

LETTER TO THE EDITOR

Open Access



Secondary analysis of malaria rapid diagnostic tests from rounds 5–8 of WHO product testing with a focus on false-negative results

Biao Xu¹, Bo Tu¹, Fang Chu¹, Mohamed Jalloh², Jin-Song Mu¹, Jun-Jie Zheng¹ and Wei-Wei Chen^{1*} 

Abstract

Despite the widespread use of malaria rapid diagnostic test (RDT) in clinical practice, there are a lot of challenges. We conducted a secondary analysis of 129 malaria RDT data from rounds 5–8 of the World Health Organization (WHO) product testing summary and discuss the causes of false-negative (FN) results with a focus on low parasite density, improper RDT storage, operation and interpretation, and *Plasmodium falciparum* with a *pfhrp2/3* gene deletion. The results demonstrated that the malaria RDTs currently commercially available might cause FN results in practice.

Keywords: Malaria, Rapid diagnostic tests, False-negative results, WHO product testing

Dear Editor,

Malaria rapid diagnostic test (RDT) is becoming the most-used method to diagnose malaria worldwide, especially in sub-Saharan Africa because malaria RDTs are easier to utilize than microscopy and have been shown to have comparable detection capability in the field [1]. Despite the widespread use of RDTs in the clinical setting, there are challenges, such as false-positive (FP) and false-negative (FN) results [2]. The World Health Organization (WHO) has conducted a systematic evaluation of the performance of commercially-available malaria RDTs since 2008, in which FP results were regarded as an important evaluation index, but FN results were not mentioned [2]. Due to the actual clinical needs, we conducted a secondary analysis of the 5th–8th rounds of

the WHO malaria RDT product testing and discuss the causes of FN results.

There were 129 RDT products enrolled into the product assessment on malaria RDT performance in this summary [3]. The summarized data were analyzed based on four measures, including low parasite density, improper RDT storage, operation and interpretation, and *Plasmodium falciparum* (Pf) with a *pfhrp2/3* gene deletion.


Low-density malaria infection is common among populations in endemic settings and potentially contributes to ongoing malaria transmission. Plucinski et al. [4] analyzed 207 outpatient samples from Angola in 2019 and showed that among histidine-rich protein 2 (HRP2)-positive patients with negative RDT results, the positive rate of quantitative RT-PCR was 45% (95% CI 35–56%). As shown in this analysis, the proportion of tests that had a panel detection score (PDS) < 80% at a low parasite density was 20–25% for Pf, which is substantially higher for *Plasmodium vivax* (Pv; Fig. 1). The results indicated that the RDT products with a lower PDS are likely to produce FN results.

*Correspondence: cww302@126.com

¹ Chinese Military Medical Expert Group in Sierra Leone, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
Full list of author information is available at the end of the article



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.



Malaria RDTs are based on capturing parasite antigen with antibodies stabilized on a nitrocellulose (organic) strip. The storage of RDTs for prolonged periods in hot or humid conditions may impair the diagnostic ability. This analysis showed that the positive rate of some products at low parasite density was impaired as the incubation temperature increased. Malaria is endemic in some geographic areas, such as sub-Saharan Africa and Southeast Asia, which are characterized by a hot, humid climate and poor storage infrastructures. As a result, RDTs were usually exposed to temperatures and humidity above the product recommended limits in these endemic areas, which may result in poor test performance.

RDTs are considered to be an ideal way for parasite-based diagnosis, particularly in remote and resource-limited areas, mainly due to the simplicity of the test. The results of this analysis showed that approximately 20–27% of products need to be improved for blood safety and instruction quality, 30–35% of RDT test bands against Pf were minimally visible, and that the RDT test bands against Pv returned a higher proportion (Additional file 1: Table S1 and Table S2). Seidahmed et al. [5] also reported that the specific errors caused by test design and manufacturer’s instructions significantly impair the accuracy of the malaria RDTs in a meso-endemic area of eastern Sudan.

The parasites have no PfHRP2 protein because the *pfhrp2* gene deletion is not recognized by the RDT antigens against PfHRP2. Given the absence of PfHRP2 protein, most of the antibodies used in RDTs for the detection of PfHRP2 also detect the PfHRP3 protein due to structural homology. Some of the parasites have combined deletions of the *pfhrp2* and *pfhrp3* genes, which result in FN results. Moreover, the parasites with deletion of the *pfhrp2/3* gene have less competition within the host and an increased probability of

transmission success. The analysis showed that for HRP2-negative Pf, most malaria RDTs have a PDS < 50% and a high FN rate (Additional file 1: Table S1). In addition, the WHO report [3] indicated that positive results on the Pf–detecting test bands were obtained against HRP2-negative samples and the band intensities were generally weak, which lead to a higher risk of FN for malaria RDTs.

In summary, the currently widely used malaria RDTs can yield FN results. Clinicians and epidemic prevention personnel must clearly understand the shortcomings of RDTs and accurately interpret those results to draw accurate judgments and treatments, and maximize the effectiveness of RDT products.

Abbreviations

FP: False-positive; FN: False-negative; HRP-2: Histidine-rich protein-2; PDS: Panel detection score; Pf: *Plasmodium falciparum*; Pv: *Plasmodium vivax*; RDT: Rapid diagnostic test; WHO: World Health Organization.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s40779-021-00345-0>.

Additional file 1. Table S1. Percentage distribution of test band intensity score against wild-type Pf in 200 parasites/μl (%). **Table S2.** Percentage distribution of test band intensity score against wild-type Pv in 200 parasites/μl (%).

Acknowledgements

We want to express our great gratitude to Professors Shui-Sen Zhou and Guang-Yu Zhao and Dr. Wei Zou for constructive comments and direction, and English language editing. We also express our thanks to International Science Editing (<http://www.internationalscienceediting.com>) for editing this manuscript.

Authors’ contributions

BX conceived, designed, and wrote the manuscript, and also analyzed and interpreted the data. BT, FC, MJ, JSM, and JJZ made substantial contributions to analyze the data and modify the manuscript. WWC conceived and

designed this research article and critically revised the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the National Grand Program on Key Infectious Disease (2018ZX10103002-001-007) and the Biosafety Special Program (19SWAQ 13).

Availability of data and materials

The datasets generated and analyzed in this study are available in Summary results of WHO product testing of malaria RDTs-Round published online of WHO homepage (<https://www.who.int/malaria/publications/atoz/9789241514965/en/-68>).

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Chinese Military Medical Expert Group in Sierra Leone, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China. ²The 34Th Military Hospital, Wilberforce Barracks, Freetown, Sierra Leone.

Received: 18 January 2021 Accepted: 14 September 2021
Published online: 07 October 2021

References

1. World Health Organization (2018). Malaria rapid diagnostic test performance: results of WHO product testing of malaria RDTs: round 8 (2016–2018). <https://apps.who.int/iris/handle/10665/276190>
2. Kavanaugh MJ, Azzam SE, Rockabrand DM. Malaria rapid diagnostic tests: literary review and recommendation for a quality assurance, quality control algorithm. *Diagnostics (Basel)*. 2021;11(5):768.
3. World Health Organization (2018). Malaria rapid diagnostic test performance: summary results of WHO product testing of malaria RDTs: round 1–8 (2008–2018). <https://apps.who.int/iris/handle/10665/276193>
4. Plucinski MM, Dimbu PR, Fortes F, Murphy SC, Smith NT, Cruz KR, et al. Malaria parasite density in individuals with different rapid diagnostic test results and concentrations of HRP2 antigen. *Am J Trop Med Hyg*. 2019;100:1202–3.
5. Seidahmed OM, Mohamedein MM, Elsir AA, Ali FT, el Malik FM, Ahmed ES. End-user errors in applying two malaria rapid diagnostic tests in a remote area of Sudan. *Trop Med Int Health*. 2008;13:406–9.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

